MIDAZOLAM
Anxiety Disorder
Theresa Jacob, PhD, MPHSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 81/ 100
Competitive context
18 Active assets in the Anxiety Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Tianjin Medical University General Hospital | Phase 4 | BBB |
Sertraline Holland Bloorview Kids Rehabilitation Hospital | Phase 4 | BBB |
Olanzapine Tianjin Medical University General Hospital | Phase 4 | BBB |
FLUOXETINE Hannover Medical School | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Theresa Jacob, PhD, MPH | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
MIDAZOLAM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →